|
|
|
|
| LEADER |
01812nam a2200361 u 4500 |
| 001 |
EB001892028 |
| 003 |
EBX01000000000000001055175 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200301 r ||| eng |
| 100 |
1 |
|
|a Cowling, Tara
|
| 245 |
0 |
0 |
|a Fluoroquinolones for the treatment of respiratory tract infections
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Tara Cowling, Kelly Farrah
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c May 6, 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (49 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Respiratory Tract Infections / drug therapy
|
| 653 |
|
|
|a Fluoroquinolones / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Anti-Bacterial Agents / therapeutic use
|
| 653 |
|
|
|a Practice Guidelines as Topic
|
| 653 |
|
|
|a Anti-Bacterial Agents / economics
|
| 653 |
|
|
|a Fluoroquinolones / economics
|
| 700 |
1 |
|
|a Farrah, Kelly
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK543514
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a This report aims to identify and synthesize the evidence describing the clinical effectiveness, cost-effectiveness, and evidence-based guidelines for the treatment of respiratory tract infections, including pneumonia and chronic obstructive pulmonary disease (COPD), using Fluoroquinolones
|